» Articles » PMID: 12075858

Increased Neopterin Production and Tryptophan Degradation in Advanced Parkinson's Disease

Overview
Specialties Neurology
Physiology
Date 2002 Jun 22
PMID 12075858
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Large amounts of neopterin are produced by interferon-(IFN)-gamma-stimulated human monocytes/macrophages, and increased neopterin concentrations indicate cellular immune activation. In parallel, IFN-gamma induces indoleamine 2,3-dioxygenase which degrades 1-tryptophan to kynurenine. Increased tryptophan degradation rates are indicated by an increased kynurenine/tryptophan ratio (kyn/trp-ratio), reflecting immune system activation, too. In 22 patients with Parkinson's disease (PD) and in 11 age-matched controls, serum and cerebrospinal fluid (CSF) neopterin concentrations were measured by ELISA. Tryptophan and kynurenine concentrations were determined by HPLC. Neopterin concentrations and kyn/trp-ratios were increased both in serum and CSF of patients as compared to controls. Serum tryptophan was lower in patients. Patients with the highest disease activity presented with highest degree of immune activation. Significant correlations existed between neopterin concentrations and kyn/trp-ratios in serum and CSF. Increased formation of neopterin and enhanced degradation of tryptophan suggest activated cell-mediated immune response in a subgroup of patients with advanced Parkinson's disease.

Citing Articles

Galantamine-Memantine Combination in the Treatment of Parkinson's Disease Dementia.

Frost E, Shi S, Byroju V, Rissardo J, Donlon J, Vigilante N Brain Sci. 2025; 14(12.

PMID: 39766362 PMC: 11674513. DOI: 10.3390/brainsci14121163.


Parkinson's disease is characterized by vitamin B6-dependent inflammatory kynurenine pathway dysfunction.

Wilson E, Umans J, Swarovski M, Minhas P, Midttun O, Ulvik A Res Sq. 2024; .

PMID: 39399688 PMC: 11469709. DOI: 10.21203/rs.3.rs-4980210/v1.


Neuroactive Kynurenines as Pharmacological Targets: New Experimental Tools and Exciting Therapeutic Opportunities.

Pocivavsek A, Schwarcz R, Erhardt S Pharmacol Rev. 2024; 76(6):978-1008.

PMID: 39304346 PMC: 11549936. DOI: 10.1124/pharmrev.124.000239.


A Review of the Evidence for Tryptophan and the Kynurenine Pathway as a Regulator of Stem Cell Niches in Health and Disease.

Summers B, Broome S, Pang T, Mundell H, Koh Belic N, Tom N Int J Tryptophan Res. 2024; 17:11786469241248287.

PMID: 38757094 PMC: 11097742. DOI: 10.1177/11786469241248287.


The Influence of Kynurenine Metabolites on Neurodegenerative Pathologies.

Pathak S, Nadar R, Kim S, Liu K, Govindarajulu M, Cook P Int J Mol Sci. 2024; 25(2).

PMID: 38255925 PMC: 10815839. DOI: 10.3390/ijms25020853.